Ocugen Inc (OCGN) advances all three late-stage modifier gene therapy programs into Phase 3 with key data readouts expected in 2027, backed by $84.6 million in cash and new licensing deals.
Ocugen (NASDAQ:OCGN) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data.
Detailed price information for Ocugen Inc (OCGN-Q) from The Globe and Mail including charting and trades.
Detailed price information for Universal Health Services (UHS-N) from The Globe and Mail including charting and trades.
Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.
Ocugen is building an international pathway for OCU400 ahead of key Phase 3 data and a planned U.S. regulatory filing next year.
Ocugen (OCGN) said Friday that its drug, OCU400, received provisional approval and priority designat
Detailed price information for Ocugen Inc (OCGN-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.